Compare, Analyse with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALKEM LABORATORIES   ACTAVIS
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
ACTAVIS
Dec-18
ALKEM LABORATORIES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,58913,860-   
Low Rs1,2329,298-   
Sales per share (Unadj.) Rs417.53,399.9-  
Earnings per share (Unadj.) Rs56.3-1,095.1-  
Cash flow per share (Unadj.) Rs64.7358.3-  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.914,023.2-  
Shares outstanding (eoy) m119.57332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.4 99.2%   
Avg P/E ratio x25.1-10.6 -237.0%  
P/CF ratio (eoy) x21.832.3 67.4%  
Price / Book Value ratio x4.80.8 583.1%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,6533,851,172 4.4%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m9,1710-   
Avg. sales/employee Rs ThNM66,912.6-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-21,552.6-  
INCOME DATA
Net Sales Rs m49,9151,130,823 4.4%  
Other income Rs m1,64521,625 7.6%   
Total revenues Rs m51,5611,152,448 4.5%   
Gross profit Rs m8,48229,633 28.6%  
Depreciation Rs m1,006483,402 0.2%   
Interest Rs m67165,255 1.0%   
Profit before tax Rs m8,451-497,399 -1.7%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0126,857 0.0%   
Tax Rs m1,606-6,303 -25.5%   
Profit after tax Rs m6,731-364,239 -1.8%  
Gross profit margin %17.02.6 648.5%  
Effective tax rate %19.01.3 1,499.6%   
Net profit margin %13.5-32.2 -41.9%  
BALANCE SHEET DATA
Current assets Rs m27,062463,804 5.8%   
Current liabilities Rs m15,324410,297 3.7%   
Net working cap to sales %23.54.7 497.0%  
Current ratio x1.81.1 156.2%  
Inventory Days Days6720 339.6%  
Debtors Days Days4166 62.3%  
Net fixed assets Rs m12,610128,003 9.9%   
Share capital Rs m2390-   
"Free" reserves Rs m34,4900-   
Net worth Rs m35,0274,664,116 0.8%   
Long term debt Rs m1,2121,642,404 0.1%   
Total assets Rs m54,3877,291,074 0.7%  
Interest coverage x13.6-6.6 -205.4%   
Debt to equity ratio x00.4 9.8%  
Sales to assets ratio x0.90.2 591.8%   
Return on assets %13.6-4.1 -331.9%  
Return on equity %19.2-7.8 -246.1%  
Return on capital %24.9-4.8 -513.5%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Net fx Rs m3,5520-   
CASH FLOW
From Operations Rs m7,259404,000 1.8%  
From Investments Rs m1,864221,946 0.8%  
From Financial Activity Rs m-9,273-693,386 1.3%  
Net Cashflow Rs m-150-67,103 0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.63 Rs / USD

Compare ALKEM LABORATORIES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ALKEM LABORATORIES With: BIOCON   VENUS REMEDIES  DR. REDDYS LAB  DR. DATSONS LABS  DIVIS LABORATORIES  



Today's Market

Slow Economy? There's Still Good Money to Be Made in the Markets(Podcast)

Indian stock markets mostly remained in the negative zone during the week except for Wednesday.

Related Views On News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks (Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years) (Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Here's Why I Recommended 15 Stocks in One Day Flat Views On News (Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid (Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

These Rebirth of India Stocks Are Raring to Compete with Tesla (The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Guide on How to Profit from Sensex 100,000.
7 Stocks to Ride the Coming Rebirth of India Rally. Full Details Here...
A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Revealed: Top 7 Stocks to Consider Buying Right Now...

ALKEM LABORATORIES SHARE PRICE


Feb 20, 2020 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - GSK PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

OTHER USEFUL LINKS

MARKET STATS